Eikon Therapeutics Inc (EIKN)

Apr 02, 2026

EIKN: Eikon Therapeutics, Inc.Comparative Chart - Zacks Investment Research

Apr 02, 2026

Mar 30, 2026

Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com India

Mar 30, 2026

Mar 30, 2026

Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com

Mar 30, 2026

Mar 30, 2026

IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates - TradingView

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics: Advancing Biopharmaceutical Innovation with Proprietary Technology Platform and Clinical-Stage Oncology Pipeline - minichart.com.sg

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics Announces Fourth Quarter and Full Year - GlobeNewswire

Mar 30, 2026

Mar 30, 2026

After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan

Mar 30, 2026

Mar 30, 2026

Eikon Therapeutics (NASDAQ: EIKN) posts 2025 loss but extends cash runway - Stock Titan

Mar 30, 2026

Mar 22, 2026

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - MarketScreener

Mar 22, 2026

Mar 10, 2026

Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 10, 2026

Mar 04, 2026

Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan

Mar 04, 2026

Mar 04, 2026

Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan

Mar 04, 2026

Mar 04, 2026

Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan

Mar 04, 2026

Mar 02, 2026

Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada

Mar 02, 2026

Mar 02, 2026

Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK

Mar 02, 2026

Mar 02, 2026

BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia

Mar 02, 2026

Mar 02, 2026

BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com

Mar 02, 2026

Mar 02, 2026

Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com

Mar 02, 2026

Mar 02, 2026

This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 02, 2026

Mar 02, 2026

Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com

Mar 02, 2026

Mar 02, 2026

BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa

Mar 02, 2026

Mar 02, 2026

Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com

Mar 02, 2026

Mar 02, 2026

Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria

Mar 02, 2026

Mar 02, 2026

JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria

Mar 02, 2026

Mar 02, 2026

Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa

Mar 02, 2026

Mar 02, 2026

Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India

Mar 02, 2026

Mar 02, 2026

JPMorgan initiates Eikon Therapeutics stock at Overweight - Investing.com

Mar 02, 2026

Mar 01, 2026

Bank of America Global Research recently announced the official initiation of research coverage on biotechnology company Eikon Therapeutics (stock code: EIKN), and assigned an initial "Buy" rating. - Bitget

Mar 01, 2026

Feb 27, 2026

Bay Area life sciences firms raise $6.1B as three companies go public - The Business Journals

Feb 27, 2026

Feb 27, 2026

Eikon Therapeutics, Inc.Common Stock (NQ: EIKN - The Chronicle-Journal

Feb 27, 2026

Feb 27, 2026

Eikon Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com

Feb 27, 2026

Feb 27, 2026

Eikon Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | EIKN | US2825641036 - marketscreener.com

Feb 27, 2026

Feb 26, 2026

Eikon Therapeutics stock drops after Wedbush downgrade By Investing.com - Investing.com Australia

Feb 26, 2026

Feb 26, 2026

Eikon Therapeutics stock drops after Wedbush downgrade - Investing.com South Africa

Feb 26, 2026

Feb 26, 2026

Wedbush initiates Eikon Therapeutics stock with underperform rating - Investing.com South Africa

Feb 26, 2026

Feb 26, 2026

Wedbush initiates Eikon Therapeutics stock with underperform rating By Investing.com - Investing.com Australia

Feb 26, 2026

Feb 24, 2026

User - The Chronicle-Journal

Feb 24, 2026

Feb 20, 2026

EIKN Should I Buy - Intellectia AI

Feb 20, 2026

Feb 18, 2026

ADIA and Platinum Falcon disclose 2.82M EIKN shares (ADIA affiliate ownership) - Stock Titan

Feb 18, 2026

Feb 12, 2026

EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 12, 2026

Feb 11, 2026

What is the current Price Target and Forecast for Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research

Feb 11, 2026

Feb 10, 2026

Insider Stock Purchases: February 10, 2026 - Quiver Quantitative

Feb 10, 2026

Feb 09, 2026

Eikon Therapeutics Prices $381 Million Initial Public Offering - Global Legal Chronicle

Feb 09, 2026